Wall Street analyst estimates for Chemomab Therapeutics Ltd. (CMMB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 2.44 |
| EV / EBITDA | -1.35 |
| Dividend Yield | 0.00% |
Price
| Price | $2.65 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: BIVI · CANF · CERO · ELAB · GLMD · INM · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CMMB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks